03:34 , Nov 19, 2014 |  BC Extra  |  Financial News

Onxeo proposes EUR 35.4M rights offering

Orphan cancer company Onxeo S.A. (Euronext:ONXEO) proposed to raise EUR 35.4 million ($44.1 million) in a rights offering underwritten by Natixis and Oddo & Cie. The company plans to issue 7.9 million shares at EUR...
07:00 , Aug 18, 2014 |  BC Week In Review  |  Company News

Topotarget, BioAlliance deal

Cancer companies BioAlliance and Topotarget completed their merger in a stock deal. The new company is Onxeo S.A. (Euronext:ONXEO, Paris, France) (see BioCentury, April 21). Topotarget A/S , Copenhagen, Denmark   BioAlliance Pharma S.A. ,...
07:00 , Aug 11, 2014 |  BC Week In Review  |  Company News

Innocutis, Onxeo sales and marketing update

Innocutis launched Sitavig acyclovir 50 mg buccal tablet in North America to treat recurrent herpes labialis. Innocutis has exclusive North American commercialization rights to the mucoadhesive formulation of acyclovir from Onxeo. Last month, BioAlliance S.A....
07:00 , Jul 28, 2014 |  BC Week In Review  |  Financial News

BioAlliance completes debt financing

BioAlliance Pharma S.A. (Euronext:BIO), Paris, France   Business: Cancer, Infectious, Drug delivery   Date completed: 2014-07-18   Type: Debt financing   Raised: EUR10 million ($13.5 million)   Investor: Financière de la Montagne   Note: The...
07:00 , Jul 21, 2014 |  BC Week In Review  |  Company News

BioAlliance, EMS deal

BioAlliance granted EMS rights to commercialize Sitavig acyclovir Lauriad in Brazil. The mucoadhesive formulation of acyclovir is approved in the U.S. and Europe for recurrent orofacial herpes. EMS will seek regulatory approval in Brazil. BioAlliance...
07:00 , Jul 21, 2014 |  BC Week In Review  |  Company News

Topotarget management update

Topotarget A/S (CSE:TOPO), Copenhagen, Denmark   Business: Cancer   Resigning: Anders Vadsholt as CEO, effective July 31 or until the approval of Topotarget’s merger with BioAlliance Pharma S.A. ; BioAlliance CEO Judith Greciet will become...
07:00 , Jul 14, 2014 |  BC Week In Review  |  Clinical News

Beleodaq belinostat regulatory update

FDA granted accelerated approval to Beleodaq belinostat from Spectrum to treat relapsed or refractory peripheral T-cell lymphoma (PTCL). The approval came more than a month ahead of the Aug. 9 PDUFA date. Spectrum plans to...
07:00 , Jul 14, 2014 |  BioCentury  |  Finance

Highlights of weekly biotech stock moves

Regulatory milestones AcelRx Pharmaceuticals Inc. (NASDAQ:ACRX) was down $0.96 to $10.54 last week after partner Gruenenthal Group submitted an MAA to EMA for Zalviso to treat moderate to severe acute pain. The submission triggered a...
22:35 , Jul 3, 2014 |  BC Extra  |  Company News

FDA approves Spectrum's belinostat

FDA granted accelerated approval to Beleodaq belinostat from Spectrum Pharmaceuticals Inc. (NASDAQ:SPPI) to treat relapsed or refractory peripheral T-cell lymphoma (PTCL). The approval came nearly a month ahead of the Aug. 9 PDUFA date. Spectrum...
07:00 , May 26, 2014 |  BC Week In Review  |  Clinical News

Livatag doxorubicin Transdrug regulatory update

BioAlliance said FDA granted Fast Track designation to Livatag to treat hepatocellular carcinoma (HCC) after treatment with sorafenib. The nanoparticle formulation of doxorubicin is in the Phase III ReLive trial to treat HCC resistant or...